Crisil Reaffirms Rating for Spandana Sphoorty Financial; Reduces Total Bank Loan Facility Limit
Spandana Sphoorty Financial Ltd has seen its rating reaffirmed by Crisil Ratings Limited, though the agency simultaneously reduced the limit set for the company’s total bank loan facilities.Crisil Ratings Limited confirmed the rating action pertaining to the company's total bank loan facilities, reaffirming the existing rating while lowering the associated credit limit. The facility is rated BBB+/Stable as of the assessment by Crisil.
The revision involves a reduction in the sanctioned amount for Total Bank Loan Facilities. As detailed below, the financial implications of the rating action are as follows:
| Facilities / Instruments | Current Limit (Rs. Crore) | Previous Limit (Rs. Crore) | Rating Action |
|---|---|---|---|
| Total Bank Loan Facilities | 1,000 | 1,700 | BBB+/Stable (Reaffirmed) |
The company received the rationale published by Crisil Ratings Limited on June 15, 2026.
SPANDANA Stock Price Movement
As of 2:43 PM, shares of Spandana Sphoorty Financial Limited are edging higher to ₹243.95 after gaining 2.31%, indicating strong performance in live trading. The stock traded within a tight intraday band, reaching a high of ₹247 and finding support at ₹240.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.